Tag: Clinical trials
Search News
Immunotherapy for advanced bladder cancer
18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Investigating new treatment options for mesothelioma
16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more
Proposed new surgery protocol for ovarian cancer
17th August 2020
For women at high risk of ovarian cancer, standard preventive practice is to offer removal of both the fallopian tubes and ovaries, but the surgery induces menopause in women who have not yet reached this stage of life. A proposed alternative two step surgical protocol, which delays the induced menopause caused by the removal of the ovaries, is highly acceptable to this premenopausal group of women.
Read more
Immunotherapy for advanced bladder cancer
29th May 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Immune therapy reduces risk of recurrence in aggressive breast cancer
27th February 2020
An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.
Read more
KEYNOTE-522: Immune therapy for breast cancer
30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more